Cellect Biotechnology (APOP) Stock: Rocketing On Clinical Results

Cellect Biotechnology APOP Stock News

Cellect Biotechnology Ltd. (NASDAQ: APOP) is making a run for the top in the market this morning, and for good reason. The company announced clinical results, exciting investors and sending the stock running for the top. Today, we’ll talk about: The clinical results; what we’re seeing from APOP stock as a result; and what we’ll … Read more

Cellect Biotechnology (APOP) Stock: Gaining On Stem Cell Breakthrough

Cellect Biotechnology Ltd. (NASDAQ: APOP) is having an overwhelmingly strong start to the trading session this morning after announcing breakthrough results surrounding stem cell technology. Of course, this led to excitement among investors, sending the stock toward the top. Below, we’ll talk about the breakthrough, what we’re seeing from the stock as a result, and … Read more

Cellect Biotechnology (APOP) Stock: Skyrocketing On First Stem Cell Transplant

Cellect Biotechnology Ltd (NASDAQ: APOP) Cellect Biotechnology is having an incredibly strong start to the trading session in the pre-market hours, and for good reason. Early this morning, the company announced its first stem cell transplant. As a result, excitement led to a frenzy among investors, pushing the stock up in a big way and … Read more

Cellect Biotechnology (APOP) Stock: Gaining Big On Positive Clinical Data

Cellect Biotechnology Ltd. (NASDAQ: APOP) Cellect Biotechnology is having an incredibly strong day in the market today. As soon as the session opened, the stock was already trading on overwhelmingly impressive gains. From there, we’ve seen a continuation of strong movement. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll … Read more

Cellect Biotechnology (APOP) Stock: Gaining Big On First Treated Patient

Cellect Biotechnology Ltd. (NASDAQ: APOP) Cellect Biotechnology is having an incredibly strong day in the market today, and for good reason. The company announced the treatment of its first blood cancer patient early this morning. Below, we’ll talk about what we’re seeing from the stock, the details with regard to the patient, and what we’ll … Read more